cabazitaxel

Optimal Chemo-Hormonal Sequencing for mCRPC Maybe Taxotere – Zytiga – Jevtana – Xtandi 

Optimal Chemo-Hormonal Sequencing for mCRPC Maybe Taxotere – Zytiga – Jevtana – Xtandi 

Optimal Chemo-Hormonal Sequencing for metastatic castrate resistant prostate cancer (mCRPC) maybe Taxotere – Zytiga – Jevtana – Xtandi

Docetaxel (Taxotere) vs. Jevtana (Cabazitaxel)

Docetaxel (Taxotere) vs. Jevtana (Cabazitaxel)

The study concluded that significantly more men preferred Jevtana compared with Taxotere (43% vs 27%), whereas 30% of the men had no preference. The most common factors influencing preferences were fatigue, pain, hair loss, and patient-defined life quality.

Adding A Platinum Drug to Chemotherapy

Adding A Platinum Drug to Chemotherapy

The study concluded that adding Carboplatin to cabazitaxel showed improved clinical efficacy compared with cabazitaxel alone for men with metastatic castration-resistant prostate cancer. Although adverse events were more common with the combination, the treatment was safe and generally well-tolerated.

What Treatment After Zytiga or Xtandi and Chemotherapy Fail?

When Xtandi or Zytiga fail what is the best next treatment? We are beginning to better understand how to sequence our advanced prostate cancer treatments, based on the CARD TRIAL using Jevtana after the failure of Zytiga Xtandi and Taxotere might be the superior route.